A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)
Oncology in Clinical Practice
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has recently been recognised, and so far approximately 200 cases have been described worldwide. From a histopathological and molecular perspective, it does not differ from classical breast anaplastic large cell lymphoma without ALK kinase expression. However, it has a different clinical course and prognosis, with a five-year survival rate about 92% as compared to 20-50% in patients with the classic form. A 60-year-old femaledoi:10.5603/ocp.2020.0007 fatcat:e364cprsezbw7lg227hl4y3txy